Frequency and Functional Impact of the c.32A>T Genetic Polymorphism of TLR7 in Women Infected With HIV-1 : the ANRS EP53 Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Frequency (%) of subjects carrying the TRL7 c.32A>T SNP in HIV-infected and healthy women
研究概览
简要总结
Short title :
X-linked biological response to HIV sensing: the ANRS EP 53 study.
Main outcome :
To demonstrate that HIV-infected women carry the TLR7 c.32A>T SNP at a higher frequency than uninfected women, arguing in favor of a role of impaired production of IFN-alpha by pDCs in the risk of becoming infected by HIV-1.
Secondary outcome :
To directly demonstrate at a single cell level that the TLR7 c.32A>T SNP is responsible for a reduce production of IFN-alpha by pDCs after activation of TLR7 by HIV-1 RNA.
Short abstract (public dissemination) :
Male and female display some differences in how their immune system responds to pathogens. This could be related to hormonal or genetic factors located on the X chromosome. This project aims at characterizing X-linked factors that can influence the innate immune response to HIV-1.
详细描述
Plasmacytoid dendritic cells (pDCs) are key actors of innate immunity that produce high levels of interferon (IFN)-alpha after activation of their Toll-Like Receptors (TLR) by pathogens. A difference between men and women has recently been shown in the level of IFN-alpha produced by pDCs after TLR activation. The production of IFN-alpha in response to TLR7 activation is higher in the presence of estrogens. This could be responsible for gender differences in the level of plasma HIV-1 RNA, that is lower in female as compared to male by about 50%, and for the sex-based differences in the susceptibility to HIV infection. Besides the role of estrogens, X-linked genetic factors could also be involved in the sex-dependent differences in the TLR7-mediated responses of pDCs. TLR7 gene is located on the X chromosome. A single nucleotide polymorphism (SNP) of the TLR7 gene, c.32A>T, have been associated with accelerated disease progression in male HIV patients, and was found over represented in female HIV as well as HCV patients, suggesting that the T allele is associated with a gender-dependent increase of susceptibility to RNA virus infections. A peripheral blood sample will be collected from HIV-infected women and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Caucasian Female
- •HIV-1 infection (ELISA and western-blot tests)
- •HIV-infection through the sexual route before 50 years-old
- •Continuous antiretroviral therapy for more than 6 months
- •Plasma HIV-1 RNA <50 copies/ml in the last 6 months
- •Age >18-year old
- •Health insurance
- •Informed consent
排除标准
- •HIV-infection through vertical or parenteral routes
- •Chronic infectious disease, notably HCV infection (hepatitis C virus)
- •Acute infectious disease
- •Auto-immune disease
- •Absence of social security (health insurance)
- •Pregnant or breastfeeding woman
- •Incapable adult
研究组 & 干预措施
HIV-infected women
A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
干预措施: A peripheral blood sample (Biological)
Healthy control women
A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
干预措施: A peripheral blood sample (Biological)
结局指标
主要结局
Frequency (%) of subjects carrying the TRL7 c.32A>T SNP in HIV-infected and healthy women
时间窗: day 1
arguing in favor of role of impaired production of IFN alpha by pDCs in the risk of becoming infected by HIV 1
次要结局
- Frequency (%) of cells expressing the "A" and "T" alleles of TRL7 in interferon-alpha producing cells(day 1 and month 3)
